Rheumatology

Dr Nehad Solman reviews the role of clinical pathways and alternative payment models in rheumatology as well as anticipated changes for 2023.

Theodore Fields, MD, FACP, discusses the most important gout studies in 2022, regulatory news, and the most pressing issues surrounding gout moving into 2023.

Potential barriers to an interest in pediatric rheumatology include inadequate exposure and mentorship within these specialties, as well as long periods of required training and lower compensation for pediatric specialists.

With a great deal of marginalized patients navigating burdensome, chronic, heterogenetic disease today, rheumatologists are becoming more invested in what the individual needs and wants from care.

The results imply the possibility of improving patient stratification based on both clinical and immune cellular phenotypes.

Fibromyalgia syndrome and connective tissue disorders were found to be highly associated in terms of both prevalence and symptoms.

What does the American College of Rheumatology recommend regarding discontinuing DMARD therapy in patients with rheumatoid arthritis? Test your knowledge with this quiz.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 17, 2022.

Nehad Soloman, MD, comments on the use of precision medicine and its advantages in the field of rheumatology.

An expert in rheumatology shares updates in clinical research that may shape rheumatic disease care in the future.

The results suggest a basis for clinicians to detect the earlier potential development of psoriasis, psoriatic arthritis, and Crohn’s disease.

“We realize, looking at the literature and also our clinical experience, that there are significant health disparities that are well documented in literature in Latinx and Hispanic rheumatoid arthritis patients, including perceptions of increased pain, fatigue, higher risk for depression, and a history of other self-help and self-management programs,” Adena Batterman, MSW, LCSW, explained.

Self-evidence can help rheumatic autoimmune disease patients gain control of symptoms when the standard of care fails them.

Improvements in GUSS, a validated tool developed to identify changes in hand osteoarthritis over time, were higher in the denosumab group when compared with placebo and the development of new erosive joints was significantly lower at week 48.

The percentage of patients with fibromyalgia experiencing alexithymia was substantially higher when compared with healthy controls and was linked to pain and psychological distress.

Beginning January 1, 2023, all new content and insights from the editorial teams of Rheumatology Network, Practical Cardiology and Endocrinology Network will be hosted on HCPLive.Com.

How do you assess if a patient with rheumatoid arthritis is in remission, and how should treatment be tapered for patients in remission? Test your knowledge with this quiz

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 10, 2022.

Dr Nehad Soloman provides insight on recent approvals and upcoming FDA submissions in biosimilars, including for lupus nephritis, and how they may change the course of rheumatic disease management moving forward.

"Fibromyalgia is best managed as a chronic condition, with non-pharmacological therapies as the primary treatment and medications as an adjunct to symptom relief.”

Nehad Soloman, MD, discusses the impact of new biosimilars to become available in the U.S. in 2023 on rheumatic disease management.

Enrollment in the FIT Teens program, which began in January 2018, was paused in March 2020 to revise operations manuals, conduct remote treatment sessions to evaluate accuracy and fidelity, obtain regulatory approvals, and train staff on the new procedures.

The incidence of gout, the most common type of inflammatory arthritis in men, has increased globally in recent decades.

“Respiratory tract infections constitute the most common infections in patients with rheumatic diseases, especially under immunosuppressive treatment,” investigators explained.

Although previous studies have indicated differential effects on cardiovascular risk between immunomodulators, results showed similar reductions across both treatment groups.

Mymee, a self-advocacy platform, utilizes technological innovation, such as self-tracking, data analytics, and expert health coaching, to improve access and offer hope to these patients by uncovering their unique triggers, managing disease flares, and improving quality of life.

"Discovering your unique triggers can feel frustrating but with the right tools and support, it is possible to find answers," Hinton-Green emphasized. "You don’t have to do it alone."

Enrollment in clinical trials across all disease states, particularly in lupus, continues to be an ongoing challenge.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 3, 2022.

Dall'Era notes that it is important for rheumatologists to understand that the current endpoints for SLE clinical trials, such as SRI-4 and BICLA, are complex and imperfect.